Navigation Links
AcelRx Pharmaceuticals Provides Clinical Trial Updates
Date:2/19/2013

he study is designed to assess the ability of sufentanil, delivered through the NanoTab System to control moderate-to-severe post-operative pain over 48 to 72 hours compared to a placebo delivered through the NanoTab System.  The study will also assess the tolerability, safety, and ease of use of the NanoTab System by nurses and patients.  Top-line results are expected in the first quarter of 2013. 
  • A second placebo-controlled Phase 3 trial with the Sufentanil NanoTab PCA System is being conducted at approximately 32 sites in patients following hip or knee replacement surgery.   Targeting enrollment of approximately 400 patients, dosing of the final subject in this study is expected around the end of the first quarter of 2013.  The primary endpoint for both the abdominal and orthopedic placebo-controlled Phase 3 studies is the sum of pain intensity difference to baseline (SPID) over 48 hours. Top-line results should be available for the orthopedic study during the second quarter of 2013.
  • Dosing of the last patient in a Phase 2, placebo-controlled, dose-finding study of the Company's ARX-04 sufentanil NanoTab product has completed.  This study, which began in November 2012, enrolled 101 patients following bunionectomy surgery, randomized into one of three groups: 20 mcg sufentanil NanoTab, 30 mcg sufentanil NanoTab or placebo.  Each dose was administered by healthcare personnel, as requested by the patient, up to a maximum of one dose every hour.  The study is designed to evaluate the ability of sufentanil NanoTabs to manage moderate-to-severe acute pain over the first 12 hours following bunionectomy surgery.  ARX-04 is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-sever acute pain, both on the battlefield and in civilian settings of trauma or injury.  AcelRx is conducting the study at two sites with funding
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
    2. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    3. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
    4. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
    5. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
    6. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
    7. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
    8. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
    9. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
    10. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    11. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- The global microbial identification market ... applications, end users, and geographies. Genotypic technology is ... identification market. This favorable growth is attributed to ... the time required for microbial identification along with ... genotypic methods have high applications in clinical diagnostics ...
    (Date:7/29/2014)... THOUSAND OAKS, Calif., July 29, 2014 Amgen ... for the second quarter of 2014. Key results include: ... million, with 8 percent product sales growth driven by ... (etanercept), Kyprolis ® (carfilzomib), Prolia ® (denosumab) ... grew 25 percent to $2.37, driven by higher revenues ...
    (Date:7/29/2014)... -- Express Scripts Holding Company (Nasdaq: ESRX ) ... Scripts stockholders of $515.2 million, or $0.67 per diluted ... Table 4, was $1.23 for the second quarter. 1 ... our clients with scale, alignment and innovative solutions to lower ... our members," stated George Paz, chairman and chief executive ...
    Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
    ... Mass., Feb. 15, 2011 Echo Therapeutics, Inc. (OTC ... the Symphony™ tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, today announced the appointment ... its Board of Directors.  Echo,s Board now has a ...
    ... Sanofi-aventis (EURONEXT: SAN and NYSE: ... announced that they have entered into a research agreement ... treat chronic wounds. This includes neuropathic diabetic foot ulcers ... that are complicated by peripheral arterial disease, commonly called ...
    Cached Medicine Technology:Echo Therapeutics Announces Appointments to Board of Directors 2Echo Therapeutics Announces Appointments to Board of Directors 3Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 2Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 3Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 4
    (Date:7/29/2014)... MO (PRWEB) July 30, 2014 ... have recently been awarded the Patient-Centered Medical Home ... the National Committee for Quality Assurance. Only one ... NCQA Level I, Level 2, or Level 3 ... participate in Patient-Centered Medical Home report faster access ...
    (Date:7/29/2014)... St. Petersburg, FL (PRWEB) July 30, 2014 Phytceramides ... explains how and why in her new book. , Today is ... Phytoceramides: Anti Aging At Its Best . The book is ... larger skin care book, but felt that Phytoceramides were ... sense to bring out this focused book now," says Kathy Heshelow, ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 1Heart ... senior communities with focus on Brain Fitness Education ... in Ventura. Brain Fitness Program Director Tee Barr ... Aegis Memory Care unit and the Assisted Living ... Aegis Life Enrichment Director Christy Rozsa and Aegis ...
    (Date:7/29/2014)... Ireland (PRWEB) July 30, 2014 Dignity ... the successful completion of a Phase I trial with ... (DGLA). , This study was a randomized, placebo-controlled, double-blind, ... assess the safety, pharmacokinetics and effect of food on ... the benign safety profile of DGLA following both single ...
    (Date:7/29/2014)... VogueQueen.com, a well-known online supplier, now allows worldwide ... garment fashion by providing graceful and sexy lingerie collection ... array of sexy dresses , designed and developed ... customers take price into consideration. Worry no more, because ... more affordable for all clients. , VogueQueen.com’s top ...
    Breaking Medicine News(10 mins):Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2
    ... Jan. 3 (HealthDay News) -- Parents can involve their children ... the works, says one fitness expert, by making exercise seem ... take the kids out for a walk this evening, most ... the video games or television?," cautioned Michael Berry, chair of ...
    ... diagnosed with schizophrenia and other psychoses appear to show ... cerebrospinal fluid in the frontal lobe compared to healthy ... report in the January issue of Archives of ... "Progressive loss of brain gray matter (GM) has been ...
    ... from visceral fat called adiponectin may play a role as ... disease (AD) in women, according to a study published Online ... the JAMA/Archives journals. The number of people affected by ... years from the current number of about 36 million people, ...
    ... HealthDay Reporter , MONDAY, Jan. 2 (HealthDay ... leaves people feeling good about themselves and positive about ... mean practicing random acts of kindness has scientifically proven ... Yes, according to a growing body of research that ...
    ... FRIDAY, Dec. 30 (HealthDay News) -- Researchers have identified ... for developing the thyroid cancer, with one in particular ... for the disease. Dr. Charis Eng, founding director ... Research Institute, said in a news release that her ...
    ... News) --,Overcrowding in emergency rooms appears to keep children ... in a timely manner, according to a new study. ... Medicine said their findings are significant since these injuries, ... and very painful. "Pain associated with long bone ...
    Cached Medicine News:Health News:Fun Ways to Include Kids in Fitness Resolutions 2Health News:Schizophrenia diagnosis associated with progressive brain changes among adolescents 2Health News:Study finds another potential risk factor for developing dementia and Alzheimer's disease in women 2Health News:With Depression, Helping Others May in Turn Help You 2Health News:With Depression, Helping Others May in Turn Help You 3Health News:Gene Mutations Linked to Thyroid Cancer Risk: Study 2Health News:Crowding in ER May Delay Pain Relief for Kids 2
    ... dedicated fluorometer from Berthold Technologies, has ... variety of measurement modes to support ... scanning, dual ratio measurements plus top ... valuable instrument for any researcher using ...
    The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
    ... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
    Small, compact and versatile, the CLK-4 light source is compatible with all Olympus fiberscopes and is ideal for the vast majority of routine fiber-endoscopic procedures, especially in the out-patien...
    Medicine Products: